Shares of DBV Technologies surged after it received positive regulatory updates in the U.S. and Europe for its Viaskin Peanut allergy patch. The stock was up 47% to $1.03 in post-market trading on ...
As many as 30% of people living with severe hemophilia A develop inhibitors such as TFPI, which can be produced by the body’s immune response to clotting factors in replacement therapy, often limiting ...